PCYT1A

Choline-phosphate cytidylyltransferase A · P49585 · PCYT1A on Sugi Atlas →

324 patent compounds predicted against PCYT1A, 311 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Encorafenib (SCHEMBL8228295)	1.00	1/20
Encorafenib (SCHEMBL8231398)	1.00	1/20
Encorafenib (SCHEMBL8512458)	1.00	1/20
Encorafenib (SCHEMBL29368575)	1.00	1/20
Encorafenib (SCHEMBL31210316)	1.00	1/20
Encorafenib (SCHEMBL23802720)	0.91	1/20
Encorafenib (SCHEMBL31098916)	0.91	1/20
SCHEMBL8236122	0.87	1/20
SCHEMBL8236124	0.87	1/20
SCHEMBL8234125	0.86	1/20
SCHEMBL8238172	0.86	1/20
SCHEMBL8240787	0.86	1/20
SCHEMBL14975895	0.86	1/20
SCHEMBL15732609	0.86	1/20
SCHEMBL20532264	0.86	1/20
SCHEMBL8232229	0.86	1/20
Encorafenib (SCHEMBL31098912)	0.86	1/20
SCHEMBL8232230	0.85	1/20
SCHEMBL20532258	0.85	1/20
SCHEMBL8241660	0.84	1/20

Clinical trials — most relevant to PCYT1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Low HDL On Six Weeks Statin Therapy (LOW) Study	PHASE4	UNKNOWN
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma	PHASE3	RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
The Association Between LPCAT1 Genetic Polymorphism and Stress Biomarkers in Neonatal Respiratory Distress Syndrome	nan	UNKNOWN
Egg Intake, Metabolic Outcomes and Choline Levels	nan	RECRUITING
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Human Requirements for the Nutrient Choline	nan	COMPLETED
Choline to Improve Malnutrition and Enhance Cognition	nan	RECRUITING
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease	nan	NOT_YET_RECRUITING
Epidemiology of Atherosclerosis	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression	nan	COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors	nan	COMPLETED
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Synergy Between Choline and DHA	nan	UNKNOWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer	nan	COMPLETED
Role of Dairy Products in Weight Maintenance	nan	COMPLETED
Genes Involved in Lipid Disorders	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PCYT1A binder may also engage these)

Protein	Name	Similarity
P49584	—	1.000	P49584 →
Q9QZC4	—	1.000	Q9QZC4 →
O74975	—	0.999	O74975 →
P49586	—	0.998	P49586 →
P19836	—	0.998	P19836 →
Q9Y5K3	—	0.996	Q9Y5K3 →
Q8BJM7	—	0.996	Q8BJM7 →
Q5SVQ0	—	0.995	Q5SVQ0 →
Q811Q9	—	0.995	Q811Q9 →
Q5HZJ0	—	0.995	Q5HZJ0 →
Q2KHP8	—	0.995	Q2KHP8 →
P49583	—	0.994	P49583 →
Q61T02	—	0.994	Q61T02 →
Q9NV66	—	0.993	Q9NV66 →
Q66624	—	0.993	Q66624 →
Q0JGK4	—	0.993	Q0JGK4 →
Q41607	—	0.993	Q41607 →
A2WYE9	—	0.993	A2WYE9 →
Q5EA26	—	0.992	Q5EA26 →
Q80WL2	—	0.992	Q80WL2 →
Q5REF9	—	0.992	Q5REF9 →
G5EGA3	—	0.992	G5EGA3 →
Q9SRW9	—	0.992	Q9SRW9 →
P55082	—	0.992	P55082 →
A5PF44	—	0.992	A5PF44 →
Q9U9K0	—	0.992	Q9U9K0 →
Q9AWM8	—	0.992	Q9AWM8 →
F4JZ68	—	0.992	F4JZ68 →
Q4V8Z3	—	0.992	Q4V8Z3 →
Q9NRR4	—	0.992	Q9NRR4 →